JPMorgan Chase & Co. Sells 106,920 Shares of Oric Pharmaceuticals, Inc. $ORIC

Key Points

• JPMorgan Chase & Co. trimmed its stake in Oric Pharmaceuticals by 8.0%, selling 106,920 shares and now holds 1,228,528 shares (about 1.26% of the company) valued at roughly $14.74 million.
• Oric's CFO Dominic Piscitelli sold 52,000 shares on Feb. 24 at an average price of $13.51, cutting his position by 43.3%; corporate insiders own 6.82% of the company.
• Analyst sentiment is broadly positive with an average rating of "Moderate Buy" and an average target price of $20.20 (11 Buy, 2 Hold, 1 Sell).

JPMorgan Chase & Co. trimmed its position in shares of Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) by 8.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,228,528 shares of the company's stock after selling 106,920 shares during the quarter. JPMorgan Chase & Co. owned approximately 1.26% of Oric Pharmaceuticals worth $14,742,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. AQR Capital Management LLC bought a new position in shares of Oric Pharmaceuticals in the first quarter valued at approximately $276,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Oric Pharmaceuticals by 8.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 40,201 shares of the company's stock worth $226,000 after acquiring an additional 3,131 shares during the last quarter. Goldman Sachs Group Inc. grew its position in Oric Pharmaceuticals by 9.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 294,784 shares of the company's stock worth $1,645,000 after acquiring an additional 24,778 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Oric Pharmaceuticals by 1,331.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 509,179 shares of the company's stock valued at $2,841,000 after purchasing an additional 473,600 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in Oric Pharmaceuticals by 56.0% during the 1st quarter. Jane Street Group LLC now owns 31,198 shares of the company's stock valued at $174,000 after purchasing an additional 11,198 shares in the last quarter. Institutional investors and hedge funds own 95.05% of the company's stock.

Oric Pharmaceuticals Trading Up 5.8%

Oric Pharmaceuticals stock opened at $12.38 on Friday. The company has a market cap of $1.24 billion, a PE ratio of -8.14 and a beta of 1.28. Oric Pharmaceuticals, Inc. has a 1 year low of $3.90 and a 1 year high of $14.93. The company's 50-day moving average is $11.70 and its two-hundred day moving average is $11.30.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings results on Monday, February 23rd. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.04. Research analysts forecast that Oric Pharmaceuticals, Inc. will post -2.17 EPS for the current year.

Insider Buying and Selling

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 52,000 shares of Oric Pharmaceuticals stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $13.51, for a total transaction of $702,520.00. Following the completion of the sale, the chief financial officer owned 68,148 shares of the company's stock, valued at approximately $920,679.48. The trade was a 43.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 6.82% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have commented on ORIC shares. Wedbush reissued an "outperform" rating and issued a $20.00 price objective on shares of Oric Pharmaceuticals in a research note on Tuesday, February 24th. Weiss Ratings restated a "sell (d-)" rating on shares of Oric Pharmaceuticals in a research note on Thursday, January 22nd. Wall Street Zen raised Oric Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Saturday, February 28th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Oric Pharmaceuticals in a research report on Monday, March 9th. Finally, HC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of Oric Pharmaceuticals in a report on Friday, March 13th. Eleven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Oric Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $20.20.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company's pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.

Want to see what other hedge funds are holding ORIC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.